Disulfiram targets cancer stem-like properties and the HER2/Akt signaling pathway in HER2-positive breast cancer

Cancer Letters

Volumn 379, Issue 1, 2016, Pages 39-48

  Kim, Ji Young ^a   Cho, Youngkwan ^a   Oh, Eunhye ^a   Lee, Nahyun ^a   An, Hyunsook ^a   Sung, Daeil ^a   Cho, Tae Min ^a   Seo, Jae Hong ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

ALDH1A1; Apoptosis; Disulfiram; HER2; P95HER2; Trastuzumab resistance

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; DISULFIRAM; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; PROTEIN KINASE B; PROTEIN P27; ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE INHIBITOR; ALDH1A1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; CDKN1B PROTEIN, HUMAN; COPPER; CUPRIC CHLORIDE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; ERBB2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER INHIBITION; CANCER STEM CELL; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BREAST NEOPLASMS; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; MCF-7 CELL LINE; METABOLISM; NUDE MOUSE; PATHOLOGY; PHENOTYPE; PHOSPHORYLATION; TIME FACTOR; TUMOR VOLUME;

ACETALDEHYDE DEHYDROGENASE INHIBITORS; ALDEHYDE DEHYDROGENASE; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; COPPER; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISULFIRAM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MCF-7 CELLS; MICE, INBRED BALB C; MICE, NUDE; NEOPLASTIC STEM CELLS; PHENOTYPE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84971491629     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.05.026     Document Type: Article

References (49)

1. Menard S., Fortis S., Castiglioni F., Agresti R., Balsari A. HER2 as a prognostic factor in breast cancer. Oncology 2001, 61(Suppl. 2):67-72.
2. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
3. DiGiovanna M.P., Stern D.F., Edgerton S.M., Whalen S.G., Moore D., Thor A.D. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J. Clin. Oncol 2005, 23:1152-1160.
4. Holbro T., Beerli R.R., Maurer F., Koziczak M., Barbas C.F., Hynes N.E. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:8933-8938.
5. Di Cosimo S., Baselga J. Management of breast cancer with targeted agents: importance of heterogeneity. [Corrected]. Nat. Rev. Clin. Oncol 2010, 7:139-147.
6. Arribas J., Baselga J., Pedersen K., Parra-Palau J.L. p95HER2 and breast cancer. Cancer Res 2011, 71:1515-1519.
7. Xia W., Liu L.H., Ho P., Spector N.L. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 2004, 23:646-653.
8. Molina M.A., Codony-Servat J., Albanell J., Rojo F., Arribas J., Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001, 61:4744-4749.
9. Ali H.R., Dawson S.J., Blows F.M., Provenzano E., Pharoah P.D., Caldas C. Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance. Breast Cancer Res 2011, 13:R118.
10. Tanei T., Morimoto K., Shimazu K., Kim S.J., Tanji Y., Taguchi T., et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin. Cancer Res 2009, 15:4234-4241.
11. Korkaya H., Paulson A., Iovino F., Wicha M.S. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 2008, 27:6120-6130.
12. Gajria D., Chandarlapaty S. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev. Anticancer Ther 2011, 11:263-275.
13. Junttila T.T., Akita R.W., Parsons K., Fields C., Lewis Phillips G.D., Friedman L.S., et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009, 15:429-440.
14. Hutchinson L. Targeted therapies: lapatinib is effective in patients with p95HER2-positive tumors. Nat. Rev. Clin. Oncol 2010, 7:358.
15. Johansson B. A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. Acta Psychiatr. Scand. Suppl 1992, 369:15-26.
16. Chen D., Cui Q.C., Yang H., Dou Q.P. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res 2006, 66:10425-10433.
17. Yip N.C., Fombon I.S., Liu P., Brown S., Kannappan V., Armesilla A.L., et al. Disulfiram modulated ROS-MAPK and NFkappaB pathways and targeted breast cancer cells with cancer stem cell-like properties. Br. J. Cancer 2011, 104:1564-1574.
18. Wang F., Zhai S., Liu X., Li L., Wu S., Dou Q.P., et al. A novel dithiocarbamate analogue with potentially decreased ALDH inhibition has copper-dependent proteasome-inhibitory and apoptosis-inducing activity in human breast cancer cells. Cancer Lett 2011, 300:87-95.
19. Triscott J., Lee C., Hu K., Fotovati A., Berns R., Pambid M., et al. Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide. Oncotarget 2012, 3:1112-1123.
20. Hothi P., Martins T.J., Chen L., Deleyrolle L., Yoon J.G., Reynolds B., et al. High-throughput chemical screens identify disulfiram as an inhibitor of human glioblastoma stem cells. Oncotarget 2012, 3:1124-1136.
21. Duan L., Shen H., Zhao G., Yang R., Cai X., Zhang L., et al. Inhibitory effect of Disulfiram/copper complex on non-small cell lung cancer cells. Biochem. Biophys. Res. Commun 2014, 446:1010-1016.
22. Chiba T., Suzuki E., Yuki K., Zen Y., Oshima M., Miyagi S., et al. Disulfiram eradicates tumor-initiating hepatocellular carcinoma cells in ROS-p38 MAPK pathway-dependent and -independent manners. PLoS ONE 2014, 9:e84807.
23. An H., Kim J.Y., Oh E., Lee N., Cho Y., Seo J.H. Salinomycin promotes anoikis and decreases the CD44+/CD24- stem-like population via inhibition of STAT3 activation in MDA-MB-231 cells. PLoS ONE 2015, 10:e0141919.
24. Oh E., Kim J.Y., Cho Y., An H., Lee N., Jo H., et al. Overexpression of angiotensin II type 1 receptor in breast cancer cells induces epithelial-mesenchymal transition and promotes tumor growth and angiogenesis. Biochim. Biophys. Acta 1863, 2016:1071-1081.
25. An H., Kim J.Y., Lee N., Cho Y., Oh E., Seo J.H. Salinomycin possesses anti-tumor activity and inhibits breast cancer stem-like cells via an apoptosis-independent pathway. Biochem. Biophys. Res. Commun 2015, 466:696-703.
26. Marcato P., Dean C.A., Pan D., Araslanova R., Gillis M., Joshi M., et al. Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells 2011, 29:32-45.
27. Vu T., Claret F.X. Trastuzumab: updated mechanisms of action and resistance in breast cancer. Front. Oncol 2012, 2:62.
28. Tay Y., Zhang J., Thomson A.M., Lim B., Rigoutsos I. MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature 2008, 455:1124-1128.
29. Kashyap V., Rezende N.C., Scotland K.B., Shaffer S.M., Persson J.L., Gudas L.J., et al. Regulation of stem cell pluripotency and differentiation involves a mutual regulatory circuit of the NANOG, OCT4, and SOX2 pluripotency transcription factors with polycomb repressive complexes and stem cell microRNAs. Stem Cells Dev 2009, 18:1093-1108.
30. Piva M., Domenici G., Iriondo O., Rabano M., Simoes B.M., Comaills V., et al. Sox2 promotes tamoxifen resistance in breast cancer cells. EMBO Mol. Med 2014, 6:66-79.
31. Nagata T., Shimada Y., Sekine S., Hori R., Matsui K., Okumura T., et al. Prognostic significance of NANOG and KLF4 for breast cancer. Breast Cancer 2014, 21:96-101.
32. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J. Clin. Invest 2009, 119:1420-1428.
33. Christiansen J.J., Rajasekaran A.K. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 2006, 66:8319-8326.
34. Han D., Wu G., Chang C., Zhu F., Xiao Y., Li Q., et al. Disulfiram inhibits TGF-beta-induced epithelial-mesenchymal transition and stem-like features in breast cancer via ERK/NF-kappaB/Snail pathway. Oncotarget 2015, 6:40907-40919.
35. van der Vegt B., de Bock G.H., Bart J., Zwartjes N.G., Wesseling J. Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer. Mod. Pathol 2009, 22:879-886.
36. Schrohl A.S., Pedersen H.C., Jensen S.S., Nielsen S.L., Brunner N. Human epidermal growth factor receptor 2 (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodies. Histopathology 2011, 59:975-983.
37. Faiman M.D., Jensen J.C., Lacoursiere R.B. Elimination kinetics of disulfiram in alcoholics after single and repeated doses. Clin. Pharmacol. Ther 1984, 36:520-526.
38. Zhang H., Chen D., Ringler J., Chen W., Cui Q.C., Ethier S.P., et al. Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo. Cancer Res 2010, 70:3996-4004.
39. McMillin G.A., Travis J.J., Hunt J.W. Direct measurement of free copper in serum or plasma ultrafiltrate. Am. J. Clin. Pathol 2009, 131:160-165.
40. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med 2001, 344:783-792.
41. Tovey S.M., Brown S., Doughty J.C., Mallon E.A., Cooke T.G., Edwards J. Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. Br. J. Cancer 2009, 100:680-683.
42. Scaltriti M., Rojo F., Ocana A., Anido J., Guzman M., Cortes J., et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J. Natl. Cancer Inst 2007, 99:628-638.
43. Kim J., Jonasch E., Alexander A., Short J.D., Cai S., Wen S., et al. Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma. Clin. Cancer Res 2009, 15:81-90.
44. Liang J., Zubovitz J., Petrocelli T., Kotchetkov R., Connor M.K., Han K., et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat. Med 2002, 8:1153-1160.
45. Wang X., Sun Y., Wong J., Conklin D.S. PPARgamma maintains ERBB2-positive breast cancer stem cells. Oncogene 2013, 32:5512-5521.
46. Lopez-Guerrero J.A., Llombart-Cussac A., Noguera R., Navarro S., Pellin A., Almenar S., et al. HER2 amplification in recurrent breast cancer following breast-conserving therapy correlates with distant metastasis and poor survival. Int. J. Cancer 2006, 118:1743-1749.
47. Geng S.Q., Alexandrou A.T., Li J.J. Breast cancer stem cells: multiple capacities in tumor metastasis. Cancer Lett 2014, 349:1-7.
48. Li H., Collado M., Villasante A., Matheu A., Lynch C.J., Canamero M., et al. p27(Kip1) directly represses Sox2 during embryonic stem cell differentiation. Cell Stem Cell 2012, 11:845-852.
49. Ithimakin S., Day K.C., Malik F., Zen Q., Dawsey S.J., Bersano-Begey T.F., et al. HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res 2013, 73:1635-1646.